<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3174">
  <stage>Registered</stage>
  <submitdate>26/05/2011</submitdate>
  <approvaldate>26/05/2011</approvaldate>
  <nctid>NCT01362426</nctid>
  <trial_identification>
    <studytitle>Paliperidone Palmitate Effectiveness Assessment Registry - Longitudinal (PEARL)</studytitle>
    <scientifictitle>A Quality Use of Medicine Clinical Registry to Assess Clinical Outcomes in Patients With Schizophrenia Treated With Intramuscular Injections of Paliperidone Palmitate</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CR018013</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - paliperidone palmitate

001 - paliperidone palmitate Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.


Treatment: drugs: paliperidone palmitate
Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of patients with symptomatic relapse</outcome>
      <timepoint>Up to 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical effectiveness and social outcomes as measured by the following clinical assessment tools: CGI-S.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical effectiveness and social outcomes as measured by HoNOS.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical effectiveness and social outcomes as measured by PSP.</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical effectiveness and social outcomes as measured by the following clinical assessment tools: GAF</outcome>
      <timepoint>Up to 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must fulfill the diagnostic criteria for Schizophrenia Disorders as defined by
             Diagnostic and Statistical Manual of Mental Disorders Version IV (DSM-IV)

          -  Must meet the approved Therapeutic Goods Administration (TGA) indication for
             injectable paliperidone palmitate

          -  Must have provided written informed consent indicating that they understand the
             purpose of and procedures required for the registry and are willing to participate in
             the registry.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Those with a known hypersensitivity to either paliperidone or risperidone, or to any
             excipients in the paliperidone palmitate formulation

          -  Employees of the clinician or study centre, with direct involvement in the proposed
             registry or other studies under the direction of that clinician or study centre, as
             well as family members of the employees or the clinician.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>127</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Bendigo</hospital>
    <hospital> - Box Hill</hospital>
    <hospital> - Elizabeth Vale</hospital>
    <hospital> - Epping</hospital>
    <hospital> - Fitzroy</hospital>
    <hospital> - Fremantle</hospital>
    <hospital> - Glenside</hospital>
    <hospital> - Meadowbrook</hospital>
    <hospital> - Waratah</hospital>
    <hospital> - Wollongong</hospital>
    <postcode> - Bendigo</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Elizabeth Vale</postcode>
    <postcode> - Epping</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Fremantle</postcode>
    <postcode> - Glenside</postcode>
    <postcode> - Meadowbrook</postcode>
    <postcode> - Waratah</postcode>
    <postcode> - Wollongong</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen-Cilag Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to determine if Australian patients with schizophrenia
      treated with paliperidone palmitate under conditions of continuous monitoring of outcomes
      over a 12-month period achieve relapse rates comparable to published literature.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01362426</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen-Cilag Pty Ltd Clinical Trial</name>
      <address>Janssen-Cilag Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>